South Korea Quasi Drug Registrations

South Korea has one of the most established and highly regulated consumer healthcare markets in Asia, creating strong opportunities for international manufacturers of quasi-drugs and hygiene-related healthcare products.

Quasi-drugs in Korea occupy a unique regulatory category positioned between cosmetics and pharmaceuticals. Products in this category typically provide mild pharmacological, preventive, disinfecting, sanitary, or hygiene-related functions and are regulated by the Ministry of Food and Drug Safety (MFDS).

Cisema supports foreign manufacturers throughout the entire Korean quasi-drug registration process, from initial feasibility assessment and classification through MFDS submission, Korean labeling, import coordination, and ongoing lifecycle compliance.

According to an MFDS report issued in April 2025, 659 quasi-drugs were successfully registered for the Korean market. While approval and notification volumes have normalized following the temporary COVID-19 surge, the Korean market continues to offer strong opportunities for overseas manufacturers seeking stable regulatory conditions and reduced competitive pressure.

Successful market entry into Korea requires accurate product classification, a clear MFDS registration strategy, compliant Korean-language documentation, and reliable local regulatory support. Depending on the product category and formulation, quasi-drugs may follow either a simplified notification pathway under Korean Standard Manufacturing Standards or a full MFDS approval process requiring individual review.

South Korea Quasi Drug Registration Services

We guide you through every step of quasi-drug registration in Korea. We assess your product category, identify the correct MFDS pathway, prepare the required documentation, and support communication with Korean authorities and relevant import bodies.

Regulatory Strategy & Classification

Determine whether your product is regulated as a quasi-drug, cosmetic, hygiene product, medical device, or pharmaceutical in Korea
Assess the applicable quasi-drug category and MFDS registration pathway
Review product composition, claims, intended use, and labeling risks before submission

Technical Documentation & Dossier Preparation

Prepare and localize quasi-drug application documentation in accordance with MFDS requirements
Support composition review, specifications, test methods, stability data, safety and efficacy documentation, and manufacturing information
Review Korean labeling, warnings, precautions, storage conditions, and advertising claims

Notification & Approval Applications

Prepare and submit quasi-drug notifications for products that meet Korean Standard Manufacturing Standards
Prepare approval applications for products requiring individual MFDS review
Manage MFDS communications, supplementary responses, and application follow-up

Import & Market Entry Support

Create and manage MFDS online business accounts and application submissions
Assist with the Entry Notice of Imported Products to the Korea Pharmaceutical Traders Association (KPTA) documentation and import clearance preparation

Post-Approval & Lifecycle Support

Ongoing regulatory compliance throughout the product lifecycle
Regulatory document management and maintenance
Strategic advice and support on license renewal, reclassification, post-approval deficiency letters, change applications and renewals

Local Authorized Representative Services for Quasi Drugs in Korea

Foreign manufacturers of quasi-drugs entering the South Korean market must work with a locally established Korean entity, known as the Korea License Holder (KLH) to manage MFDS registration, importation, regulatory communication, and lifecycle compliance. This local license holder acts as the manufacturer’s in-country regulatory representative and is responsible for ensuring that the registered product continues to meet Korean requirements after approval or notification.

For overseas manufacturers, the KLH is not simply an administrative contact. It plays a central role in maintaining access to the Korean market and may control product registrations, regulatory filings, import documentation, and communications with MFDS and other relevant Korean bodies.

While appointing a distributor as the local license holder may appear convenient, it can create long-term limitations around certificate control, distributor changes, confidentiality, and commercial flexibility. Many manufacturers therefore prefer to appoint an independent regulatory partner to help maintain control over registrations while keeping distribution options open.

As your independent Korean license holder and regulatory partner, Cisema supports quasi-drug registration, MFDS communication, import coordination, labeling compliance, and lifecycle maintenance, helping you enter and remain in the Korean market with greater transparency, flexibility, and control.

‍

Korea Legal Representation

Acting as local authorized representative and Korea License Holder (KLH)
MFDS communication and regulatory liaison
Regulatory representation before Korean authorities
Management of importer obligations

Regulatory Coordination

Ongoing regulatory updates
Inspection coordination and support during regulatory reviews
Customs, import, and KPTA coordination support

Regulatory Compliance

Regulatory document management and maintenance
Korean labeling, IFU localization, and compliance support
Support for Korean quasi-drug notification and approval maintenance

Post-Market Vigilance

Support adverse event reporting and regulatory notifications
Coordinate recalls, corrective actions, and safety communications
Support ongoing compliance with Korean post-market obligations

Regulatory Strategy

Assess product classification and applicable Korean regulatory pathways
Advise on approval strategy, import planning, and market entry requirements
Support long-term regulatory planning and lifecycle management in Korea

Global Communication

Provide multilingual support in English, Mandarin, German, and more
Align with your commercial, regulatory, and quality teams across time zones.

Why Work with Cisema?

One Partner, Full Lifecycle Support

From pre-market strategy to post-market compliance, we provide support to internal regulatory teams and ensure seamless lifecycle management.

Regional Reach, Global Presence

Based in Asia and Europe with a global team delivering global reach.

Cross-Industry Expertise

Pharma, biotech, medical devices, cosmetics, supplements, veterinary, industrial and consumer goods.

Proven Results

Over 20 years of regulatory submissions, regulatory expertise, and approvals to drive business success.

Role of a China Agent

Read the Latest Regulatory News

View More

Beijing MPA Clarifies Electronic Customs Clearance Pilot for Imported Drugs

Beijing's pilot allows companies to download and print approved import clearance documents digitally, reducing paperwork while maintaining existing regulatory requirements.

November 18, 2026
Beijing MPA Clarifies Electronic Customs Clearance Pilot for Imported Drugs

Indonesia Extends Mandatory Halal Certification Deadlines

Indonesia extends halal certification deadlines for medicines, medical devices, cosmetics, and other regulated products, giving additional time to meet compliance requirements.

November 3, 2026
Indonesia Extends Mandatory Halal Certification Deadlines

NMPA Releases Draft Measures on Market Exclusivity for Pediatric & Orphan Drugs

Learn how China’s proposed measures could affect market exclusivity for pediatric and rare disease drugs, including eligibility, filing timelines, and supply obligations.

October 29, 2026
NMPA Releases Draft Measures on Market Exclusivity for Pediatric & Orphan Drugs

China Targets 25% of Global First-in-Class Drugs in New 2030 Biopharma Plan

China’s 2026–2030 pharmaceutical plan sets ambitious targets to turn its biopharma sector into a global innovation engine, reshaping international competition, licensing, and regulation.

October 29, 2026
China Targets 25% of Global First-in-Class Drugs in New 2030 Biopharma Plan

Malaysia NPRA Announces Year-End Payment Service Closure for 2026

Plan ahead for Malaysia NPRA’s 2026 year-end payment closure, featuring key deadlines for QUEST3+ online transactions and the Revenue Counter.

October 26, 2026
Malaysia NPRA Announces Year-End Payment Service Closure for 2026

China Strengthens Priority Provision and Use of Essential Medicines

China’s latest policy sets new requirements for hospital medicine catalogs, prescribing practices, clinical evaluation, and performance-linked funding

October 29, 2026
China Strengthens Priority Provision and Use of Essential Medicines
Previous
Previous

Cisema's South Korea Office

Cisema KOREA

#511, DaeryungTech Town 21st
1126 Beoman-ro, Geumcheon-gu
Seoul 05698
Republic of Korea

Contact Us

Get in Touch with Our South Korea Team

And discover how we can support you in achieving approval for your quasi-drug product in South Korea.

Talk to an Expert